Receptors, Estrogen

• 

  Subject Areas on Research

  • 17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells. 
  • 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. 
  • 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. 
  • A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. 
  • A joint analysis of metabolomics and genetics of breast cancer. 
  • A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. 
  • A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. 
  • A negative coregulator for the human ER. 
  • A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. 
  • A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. 
  • A reevaluation of the concept of separable periods of organizational and activational actions of estrogens in development of brain and behavior. 
  • A role for the androgen receptor in the treatment of male breast cancer. 
  • A tamoxifen inducible knock-in allele for investigation of E2A function. 
  • ASO Visual Abstract: Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. 
  • Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. 
  • Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. 
  • Acquisition of metastatic tissue from patients with bone metastases from breast cancer. 
  • Actions of steroids in mitochondria. 
  • Additive estrogenic activities of a binary mixture of 2',4',6'-trichloro- and 2',3',4',5'-tetrachloro-4-biphenylol. 
  • Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. 
  • Ager-CreERT2: A New Genetic Tool for Studying Lung Alveolar Development, Homeostasis, and Repair. 
  • Aggressive fibromatosis. 
  • Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. 
  • Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis. 
  • Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. 
  • Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. 
  • Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone. 
  • Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. 
  • Application of random peptide phage display to the study of nuclear hormone receptors. 
  • Are all aromatase inhibitors alike? 
  • Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype. 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Autoradiographic analysis of nuclear estrogen binding sites during postnatal development of the genital tract of female mice. 
  • Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. 
  • BRCA1 expression is not directly responsive to estrogen. 
  • Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. 
  • Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. 
  • Biological assessments of a mixture of endocrine disruptors at environmentally relevant concentrations in water following UV/H2O2 oxidation. 
  • Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. 
  • Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors. 
  • Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women. 
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. 
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. 
  • Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy. 
  • Breast cancer survival in African-American women by hormone receptor subtypes. 
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. 
  • CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC. 
  • CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. 
  • CNS location of uterine-related neurons revealed by trans-synaptic tracing with pseudorabies virus and their relation to estrogen receptor-immunoreactive neurons. 
  • Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. 
  • Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. 
  • Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells-in vitro and ex vivo study. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor. 
  • Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. 
  • Cholesterol and breast cancer pathophysiology. 
  • Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. 
  • Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. 
  • Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. 
  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care. 
  • Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. 
  • Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods. 
  • Coactivator AIB1 links estrogen receptor transcriptional activity and stability. 
  • Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor. 
  • Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. 
  • Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. 
  • Comparative analyses of mechanistic differences among antiestrogens. 
  • Comprehensive molecular portraits of human breast tumours. 
  • Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. 
  • Connections and regulation of the human estrogen receptor. 
  • Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment. 
  • Creation of an active estrogen-responsive element by a single base change in the flanking sequence of a cellular oncogene: a possible mechanism for hormonal carcinogenesis? 
  • Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. 
  • Cystosarcoma phylloides. A steroid receptor and ultrastructure analysis. 
  • Cytochemistry of sex steroid receptors: a critique. 
  • Death-associated protein kinase 1 promotes growth of p53-mutant cancers. 
  • Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. 
  • Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. 
  • Definition of the molecular basis for estrogen receptor-related receptor-alpha-cofactor interactions. 
  • Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators. 
  • Determination of estrogen receptor messenger ribonucleic acid (mRNA) and cytochrome P450 aromatase mRNA levels in adipocytes and adipose stromal cells by competitive polymerase chain reaction amplification. 
  • Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. 
  • Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. 
  • Development of peptide antagonists that target estrogen receptor-cofactor interactions. 
  • Differential biomarker gene and protein expressions in nonylphenol and estradiol-17beta treated juvenile rainbow trout (Oncorhynchus mykiss). 
  • Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer. 
  • Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta. 
  • Differential molecular mechanism of the estrogen action that regulates lactoferrin gene in human and mouse. 
  • Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. 
  • Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. 
  • Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements. 
  • Disruption of the mouse oestrogen receptor gene: resulting phenotypes and experimental findings. 
  • Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. 
  • Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. 
  • Dynamic exchange at regulatory elements during chromatin remodeling underlies assisted loading mechanism. 
  • Dynamic shuttling and intranuclear mobility of nuclear hormone receptors. 
  • Dynamics of the epigenetic landscape during erythroid differentiation after GATA1 restoration. 
  • ERRgamma regulates cardiac, gastric, and renal potassium homeostasis. 
  • ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. 
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. 
  • Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. 
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. 
  • Effects of Pubertal Exposure to Dietary Soy on Estrogen Receptor Activity in the Breast of Cynomolgus Macaques. 
  • Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice. 
  • Effects of estrogen on very low density lipoproteins (VLDL) synthesis in avian liver slices in vitro: lack of correlation with nuclear estrogen receptors. 
  • Effects of genistein or soy milk during late gestation and lactation on adult uterine organization in the rat. 
  • Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. 
  • Embryonic expression and steroid regulation of brain aromatase cyp19a1b in zebrafish (Danio rerio). 
  • Endocrine therapy in metastatic breast cancer. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels. 
  • Endometrial receptivities after leuprolide suppression and gonadotropin stimulation: histology, steroid receptor concentrations, and implantation rates. 
  • Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. 
  • Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. 
  • Estrogen Receptor Signaling in the Immune System. 
  • Estrogen and thyroid hormone interaction on regulation of gene expression. 
  • Estrogen modulation of nuclear matrix-associated steroid hormone binding. 
  • Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. 
  • Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. 
  • Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: a marker of hormone response. 
  • Estrogen receptor determination in percutaneous bone marrow biopsies of patients with metastatic breast cancer. 
  • Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. 
  • Estrogen receptor interconversion, factors regulating conformation and functions. 
  • Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. 
  • Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. 
  • Estrogen receptor-cofactor interactions as targets for novel drug discovery. 
  • Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model. 
  • Estrogen stimulates the transient association of calmodulin and myosin light chain kinase with the chicken liver nuclear matrix. 
  • Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. 
  • Estrogen-Related Receptor Alpha: An Under-Appreciated Potential Target for the Treatment of Metabolic Diseases. 
  • Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. 
  • Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. 
  • Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. 
  • Estrogen-related receptor alpha as a therapeutic target in cancer. 
  • Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. 
  • Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. 
  • Estrogen-related receptors stimulate pyruvate dehydrogenase kinase isoform 4 gene expression. 
  • Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis. 
  • Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergism. 
  • Estrogenic responses of larval sunshine bass (Morone saxatilis x M. Chrysops) exposed to New York City sewage effluent. 
  • Estrogens and prostate cancer. 
  • Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. 
  • Evaluation of a recombinant yeast cell estrogen screening assay. 
  • Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. 
  • Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. 
  • Expression of functional estrogen receptor beta in locus coeruleus-derived Cath.a cells. 
  • Expression of nuclear estrogen-binding sites within developing human fetal vagina and urogenital sinus. 
  • Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. 
  • Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience. 
  • Fasting-induced hepatic production of DHEA is regulated by PGC-1alpha, ERRalpha, and HNF4alpha. 
  • Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. 
  • Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma. 
  • Frequency of breast cancer subtypes among African American women in the AMBER consortium. 
  • From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). 
  • Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. 
  • Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. 
  • G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • GPER1 is required to protect fetal health from maternal inflammation. 
  • Gender differences in molecular remodeling in pressure overload hypertrophy. 
  • Gene expression profiling for prediction of clinical characteristics of breast cancer. 
  • Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. 
  • Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. 
  • Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. 
  • Genomic structure and embryonic expression of estrogen receptor beta a (ERbetaa) in zebrafish (Danio rerio). 
  • High level expression of biologically active estrogen receptor in Saccharomyces cerevisiae. 
  • Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. 
  • Hormonal and personal effects on estrogen receptors in breast cancer. 
  • Hormone therapy: physiological complexity belies therapeutic simplicity. 
  • Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. 
  • Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. 
  • Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. 
  • Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins. 
  • Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. 
  • Identification of a negative regulatory function for steroid receptors. 
  • Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. 
  • Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. 
  • Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. 
  • Identification of a third autonomous activation domain within the human estrogen receptor. 
  • Identification of an enhancer element in the estrogen receptor upstream region: implications for regulation of ER transcription in breast cancer. 
  • Identification of novel steroid-response elements. 
  • Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. 
  • Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. 
  • Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. 
  • Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. 
  • Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. 
  • In situ distinction between steroid receptor binding and transactivation at a target gene. 
  • In vivo modulation of 17 beta-estradiol-induced vitellogenin synthesis and estrogen receptor in rainbow trout (Oncorhynchus mykiss) liver cells by beta-naphthoflavone. 
  • Increased expression of estrogen receptor beta in pachytene spermatocytes after short-term methoxyacetic acid administration. 
  • Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. 
  • Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. 
  • Inhibition of ERRα Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. 
  • Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. 
  • Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblasts during differentiation. 
  • Interaction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. 
  • Interactions of estrogen- and thyroid hormone receptors on a progesterone receptor estrogen response element (ERE) sequence: a comparison with the vitellogenin A2 consensus ERE. 
  • Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. 
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 
  • Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. 
  • Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. 
  • Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. 
  • Investigation of antiestrogenic properties of unleaded gasoline in female mice. 
  • Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. 
  • Lactoferrin gene expression is estrogen responsive in human and rhesus monkey endometrium. 
  • Laser scanning cytometry quantification of estrogen receptors in breast cancer. 
  • Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. 
  • Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer. 
  • Long-term prognostic implications of sex-steroid receptors in human cancer. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Magnetic separation to concentrate the estrogen receptor from adipose tissue for western analysis. 
  • Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. 
  • Malignant effusions in recurrent breast cancer: steroid hormone receptor analysis of effusion fluid derived cells. 
  • Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. 
  • Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. 
  • Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. 
  • Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. 
  • Mesothelin, a novel immunotherapy target for triple negative breast cancer. 
  • Mining the complexities of the estrogen signaling pathways for novel therapeutics. 
  • Modulation of estrogen receptor levels in mouse uterus by protein kinase C isoenzymes. 
  • Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. 
  • Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. 
  • Molecular cloning of rainbow trout (Oncorhynchus mykiss) eggshell zona radiata protein complementary DNA: mRNA expression in 17beta-estradiol- and nonylphenol-treated fish. 
  • Molecular mechanics simulation of the interaction of estrogen receptor with estrogen regulatory element. 
  • Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. 
  • Mouse retinal pigmented epithelial cell lines retain their phenotypic characteristics after transfection with human papilloma virus: a new tool to further the study of RPE biology. 
  • Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. 
  • Mutational analysis of the estrogen-receptor gene in endometrial carcinoma. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • Neuroendocrine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. 
  • Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. 
  • Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. 
  • Novel Hormone Receptors Present in Apocrine Cystadenoma of the Eyelid. 
  • Novel Transcriptional Mechanisms for Regulating Metabolism by Thyroid Hormone. 
  • Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. 
  • Nuclear estrogen receptor in the avian liver: correlation with biologic response. 
  • Obesity and body fat distribution and breast cancer prognosis. 
  • Oestrogen receptors enhance dopamine neurone survival in rat midbrain. 
  • On the intractability of estrogen-related receptor alpha as a target for activation by small molecules. 
  • Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. 
  • Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. 
  • PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle fiber types. 
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. 
  • Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. 
  • Paradoxical relationship between chromosomal instability and survival outcome in cancer. 
  • Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models. 
  • Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. 
  • Pathology and pathophysiology of uterine smooth-muscle tumors. 
  • Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset. 
  • Peptide antagonists of the human estrogen receptor. 
  • Performance of preoperative breast MRI based on breast cancer molecular subtype. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. 
  • Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. 
  • Poor Endometrial Proliferation After Clomiphene is Associated With Altered Estrogen Action. 
  • Population and target considerations for triple-negative breast cancer clinical trials. 
  • Potency of combined estrogenic pesticides. 
  • Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer. 
  • Predicting the clinical status of human breast cancer by using gene expression profiles. 
  • Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. 
  • Problems for risk assessment of endocrine-active estrogenic compounds. 
  • Progesterone Signaling in Endometrial Epithelial Organoids. 
  • Progesterone receptor activity in leiomyomatosis peritonealis disseminata. 
  • Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. 
  • Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. 
  • Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. 
  • Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors. 
  • Prostatic mucinous adenocarcinoma. A Cowper gland carcinoma mimicker. 
  • Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. 
  • Protein kinase C modulates estrogen receptors in differentiated osteoblastic cells in vitro. 
  • Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 
  • Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. 
  • Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. 
  • Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. 
  • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. 
  • Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. 
  • Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. 
  • Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. 
  • Receptor interconversion model of hormone action. 2. Requirement of both kinase and phosphatase activities for conferring estrogen binding activity to the estrogen receptor. 
  • Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs. 
  • Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. 
  • Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. 
  • Relationship between adipose stromal-vascular cells and adipocytes in human adipose tissue. 
  • Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. 
  • Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. 
  • Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. 
  • Risk factors for estrogen receptor-positive breast cancer. 
  • Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. 
  • Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. 
  • Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. 
  • Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. 
  • S-nitrosylation of Ras in breast cancer. 
  • Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen. 
  • Sex steroid receptor analysis in human melanoma. 
  • Sex steroid receptor concentration in breast carcinoma tissue: effect of devascularization during mastectomy. 
  • Smoothing spline-based score tests for proportional hazards models. 
  • Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma. 
  • Steroid hormone receptors selectively affect transcriptional activation but not basal repression by thyroid hormone receptors. 
  • Structural organization and regulation of the chicken estrogen receptor. 
  • Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. 
  • Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. 
  • Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. 
  • Targeting mutant estrogen receptors. 
  • Temporal control of gene deletion in sensory ganglia using a tamoxifen-inducible Advillin-Cre-ERT2 recombinase mouse. 
  • Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor. 
  • The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. 
  • The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. 
  • The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. 
  • The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. 
  • The effects of NSAIDs on breast cancer prognostic factors. 
  • The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. 
  • The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. 
  • The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. 
  • The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. 
  • The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. 
  • The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. 
  • The molecular determinants of estrogen receptor pharmacology. 
  • The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. 
  • The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. 
  • The molecular pharmacology of ovarian steroid receptors. 
  • The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? 
  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. 
  • The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. 
  • Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function. 
  • Toxicology of environmental estrogens. 
  • Transactivation functions facilitate the disruption of chromatin structure by estrogen receptor derivatives in vivo. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. 
  • Type and duration of exogenous hormone use affects breast cancer histology. 
  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. 
  • Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
  • Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. 
  • Validation of a breast cancer risk prediction model developed for Black women. 
  • WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. 
  • What threshold for adjuvant therapy in older breast cancer patients? 
  • Whole-genome analysis informs breast cancer response to aromatase inhibition. 
  • [Treatment of primary cancer of the breast in elderly women. Role of hormone therapy]. 
  • p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Shinohara, Mari L., Associate Professor of Immunology, Cell Biology